Participants had a mean age of 55.1 years (SD = 14), were predominantly female, and primarily cared for a parent. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Across the literature, it is evident that health inequalities currently exist and exacerbate the disparities in the care of BAME dementia patients. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a progressive neurodegenerative disorder that represents a growing challenge to global health, especially in aging populations. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Future research should leverage perspectives of former caregivers to assist with improving outcomes for Black caregivers, thereby promoting health equity. [ Journal of Gerontological Nursing, 51 (6), 30–37.] 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The FFMQ-15 may reflect different experiences of mindfulness among Black caregivers of PWD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dementia, including Alzheimer’s disease and related dementias (ADRD), is a major cause of death among older adults in the United States. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Despite having an increased risk of developing dementia, individuals from minority ethnic communities are largely overlooked by research and dementia services and are less likely to receive timely diagnosis and appropriate support. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Individuals aged 70 and above experiencing memory loss in Cochran and Parmer Counties had a statistically significant association with cognitive impairment (p < 0.001). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The results presented are sufficiently encouraging to recommend that the DEMQOL instruments be used alongside a generic measure such as the European Quality of Life-5 Dimensions (EQ-5D) in future studies of interventions in dementia as there was evidence that they can be more sensitive for patients at the milder end of disease and some limited evidence that the person with dementia measure may be able to reflect deterioration. 2 key findings →
Design: clinical trial Participants: 644 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Arthritis includes approximately 100 conditions that affect the joints and surrounding tissues. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The prevalence of dementia in older people in Seoul appears to be somewhat lower than in rural areas of Korea. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Twenty-two primary studies were included. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The “WarioWare: Move It!” intervention significantly improved physical flexibility, joint range of motion, motor coordination, hand dexterity, and cognitive function among older adults with mild cognitive impairment or dementia residing in rural LTCFs. 5 key findings →
Participants: 232 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Despite elevated risk profiles for dementia, Black women are often absent in cultural narratives about dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Persistent racial disparities in dementia raise concerns regarding the validity and generalizability of existing prognostic models across diverse populations. 2 key findings →
Participants: 55,004 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
INTRODUCTIONThe number of people living with dementia in many African countries is anticipated to treble by 2050. 1 key finding →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BackgroundMultimorbidity is common among U.S. skilled nursing facilities (SNFs) residents and complicates pharmacologic management, yet real-world evidence on treatment patterns in this population remains limited. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
NST showed stable cross-cohort structure (Mantel r = 0.71-0.77) and differentiated MCI (d = -0.39) and AD biomarker status (d = -0.23). 4 key findings →
Design: longitudinal study Participants: 1,479 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
AADAPt participants had risk factors for developing dementia in future, such as hypertension and hyperlipidemia, but also reported protective factors such as high social engagement. 4 key findings →
Design: longitudinal study Participants: 177 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Subjective cognitive decline (SCD), the self-reported experience of worsening or more frequent memory loss or confusion, might be a symptom of early-stage dementia or future serious cognitive decline such as Alzheimer disease* or a related dementia (ADRD) (1). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recorded PD-related mortality was lower among Black than White adults, whereas AD-related mortality showed no statistically significant racial difference. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This nationwide study provides epidemiological data on dementia and MCI among adults aged ≥ 60 years across all 12 administrative regions of Morocco. 1 key finding →
Design: cross-sectional Participants: 1,662 Evidence: low
Full summary, score breakdown and related studies → Original source
Memory IIV may be more closely linked to hippocampal white matter, while mean memory performance may better reflect hippocampal volume. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study reports the prevalence of CF among elderly hypertensive residents of a community in Inner Mongolia. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Drama therapy is in an accelerated growth phase, with substantial scholarly expansion expected over the next two decades. 4 key findings →
Participants: 785 Evidence: high
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →